louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05979467: The Relationship Between Serum Endocan and ADMA Levels and Penile Doppler Ultrasonography in Erectile Dysfunction
Official title: The Relationship Between Serum Endocan and ADMA Levels and Penile Doppler Ultrasonography Findings in Patients With Vasculogenic Erectile Dysfunction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Evaluation of the Relationship Between Serum Biomarkers (Endocan and ADMA) and Penile Doppler Ultrasonography Findings of Patients With Severe Erectile Dysf
Keywords: Erectile dysfunction
Endocan
ADMA
Penile Doppler
Lead sponsor: Ankara Etlik City Hospital
Sponsor class: OTHER_GOV
First posted: 2023-08-07
Enrollment: 73
Sex: MALE
Minimum age (years): 50
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: tertiary care clinic

Brief summary: The gold standard diagnosis in patients admitted to the hospital with the complaint of erectile dysfunction is penile doppler ultrasonography. This procedure is an invasive procedure and can cause various complications. Therefore, in this study, we aimed to support and define the diagnosis of erectile dysfunction with some biomarkers that can be measured in blood samples. At this point, we performed penile doppler ultrasonography, which is the gold standard test, for all patients who applied with the complaint of erectile dysfunction, and compared the results of penile doppler and serum biomarkers in the patients.


Eligibility criteria: Inclusion Criteria:

* Patients with severe erectile dysfunction according to International Index of Erectile Function-15 questionnaire
* Patients who have not received medical or surgical treatment before
* Patients without comorbidity and related drug use

Exclusion Criteria:

* Patients who have had previous pelvic trauma or surgery,
* Patients who have benefited from using phosphodiesterase-5 enzyme inhibitors,
* Patients with psychogenic erectile dysfunction and moderate or mild erectile dysfunction according to International Index of Erectile Function-15 questionnaire,
* Patients who have neurological disease, chronic liver disease and patients with chronic renal failure and those who used drugs that could cause erectile dysfunction

Primary outcomes:
measure: To evaluate the relationship between serum endocan (endothelial cell-specific molecule-1), ADMA (asymmetric dimethylarginine) values and penile Doppler ultrasonography findings in patients with severe Erectile dysfunction.
timeFrame: 10 days from the outpatient clinic admission
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara City Hospital Bilkent
Study officials:
References:
Clinical trial NCT02578667: Gorbly Compression Device for Use in Image-guided Procedures
Official title: Gorbly Compression Device for Use in Image-guided Procedures
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Neoplasm
Sepsis
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: Wallace H Coulter Center for Translational Research
First posted: 2015-10-19
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL

Brief summary: Prospective cohort study. All patients presenting for percutaneous abdomino-pelvic soft tissue ablation, biopsy, or drainage performed under the care of Dr. Issam Kably will become part of the study population. Based on prior imaging and/or imaging at the time of the procedure, patients will fall into two groups, those for whom no compression is necessary to complete the procedure and those for whom compression may provide benefit. These would be selected based on Dr. Kably's experience as a practicing academic, fellowship-trained, and CAQ'ed interventional radiologist. The latter group would then further subdivide into those who give consent for use of the compression device and those who do not consent. Results of each group would be measured including the following: termination versus successful completion of the procedure; adverse events including bleeding or damage to surrounding structures necessitating further medical or surgical intervention.


Eligibility criteria: Inclusion Criteria:

* All-comers presenting for percutaneous abdomino-pelvic soft tissue ablation, biopsy, or drainage .

Exclusion Criteria:

* Open surgical or traumatic abdominal wall.
* Active abdominal wall infection.

Primary outcomes:
measure: The percentage of procedures (i.e., ablations, biopsies, or drainages) that are allowed successful completion.
timeFrame: intraoperative
Secondary outcomes:
measure: The rate of complication of bleeding or damage to the surrounding vessels or organs by use of the compression device.
timeFrame: intraoperative
Other outcomes:
Locations:
city: Miami
country: United States
facility: Jackson Memorial Hospital
state: Florida
Study officials:
affiliation: University of Miami
name: Issam Kably, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05884567: Effectiveness of Neck Isometric Exercises and Cervical Mobilization on Cervical Radiculopathy
Official title: Effectiveness of Neck Isometric Exercises and Cervical Mobilization on Cervical Radiculopathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervical Radiculopathy
Lead sponsor: Neuro Counsel Hospital, Pakistan
Sponsor class: OTHER
Collaborators: name: Al Nafees Medical Hospital, Islamabad
name: National Institute of Rehabilitation Medicine, Islamabad, Pakistan
First posted: 2023-06-01
Enrollment: 30
Sex: ALL
Minimum age (years): 25
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A single blind RCT
Primary purpose: OTHER

Brief summary: Effectiveness of neck isometric exercises and cervical mobilization will be compared to observe the efficacy of these techniques on cervical radiculopathy

Detailed description: Two groups will be formed to observe the efficacy of neck isometric exercises and cervical mobilization on cervical radiculopathy by using NPRS, ROM and QoL tools.

Eligibility criteria: Inclusion Criteria:

* Males and females with age between 25-50 years
* Patients referred from neuro and orthopedic departments with diagnosed cervical radiculopathy.
* Complaint of neck pain on neck bending with positive spurling's test.
* Complaint of neck pain, numbness and tingling in arm with positive spurling's test.

Exclusion Criteria:

* Cervical Trauma
* Any other orthopedic and neurological conditions of cervical spine.
* Fracture
* Malignancy

Primary outcomes:
measure: Numeric Pain Rating Scale
timeFrame: 4 weeks
measure: Range of motion
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Al Nafees Medical Hospital, Islamabd
state: Federal
Study officials:
References:
Clinical trial NCT05798767: Preoperative Cognitive Impairment Predicts Postoperative Delirium
Official title: Preoperative Cognitive Impairment Predicts Postoperative Delirium in Elderly Patients Undergoing General Anesthesia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Delirium in Old Age
Neurocognitive Disorders
Cognitive Impairment
Lead sponsor: Henan Provincial People's Hospital
Sponsor class: OTHER
First posted: 2023-04-05
Enrollment: 150
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Elderly patients attending Henan Provincial People's Hospital during the trial period who required elective thoracic surgery

Brief summary: Preoperative cognitive impairment (PCI) may increase the incidence of postoperative delirium (POD), yet screening for cognitive impairment is rarely performed. This study hypothesized that Mini-Cog for preoperative cognitive impairment screening predicts postoperative delirium. Elderly patients (65 years or older) attending Henan Provincial People's Hospital during the trial period who required elective thoracic surgery were recruited into the study.

Detailed description: We collected data points on demographics and hospital episodes through the electronic medical record the day before surgery. Cognitive function screening (Mini-Cog; the Mini-mental State Examination, MMSE), depression screening (Patient Health Questionnaire-9, PHQ-9), sleep quality assessment (Pittsburgh Sleep Quality Index, PSQI), and pain assessment (Numeric Rating Scale, NRS) were performed, and the time spent on Mini-Cog test and MMSE assessment was recorded. The Short Confusion Assessment Method (CAM) was administered once per day on postoperative days 1 to 5 to evaluate delirium.

Eligibility criteria: Inclusion Criteria:

1. 65 years of age or older,
2. elective thoracic surgery,
3. under general anesthesia.

Exclusion Criteria:

1. history of psychiatric disorders,
2. use of any antipsychotic drugs,
3. ASA score \>3
4. severe visual, hearing, or physical dysfunction unable to complete the scale
5. advanced malignant tumors of the chest with distant metastases to bone, liver, etc.,
6. history of general anesthesia surgery in the last six months.

Primary outcomes:
measure: delirium
timeFrame: February 2022 to March 2023
Secondary outcomes:
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: Henan People's Hospital
Study officials:
References:
Clinical trial NCT02560467: Perfusion Imaging With Myocardial Contrast Echocardiography in HCM
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hypertrophic Cardiomyopathy
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
First posted: 2015-09-25
Enrollment: 10
Sex: ALL
Minimum age (years): 19
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The objective of this study is to determine whether myocardial contrast echocardiography in patients with cardiomyopathy (HCM) can detect resting hypo-perfusion due to fibrosis or stress induced perfusion defects due to associated abnormalities in intramyocardial arteries and the microcirculation. A secondary aim will be to determine whether abnormalities in perfusion are associated with either severity of symptoms (chest pain and dyspnea), presence of arrhythmias, and regional function of the septum.


Eligibility criteria: Inclusion Criteria:

* Age 18-80 years
* Established diagnosis of HCM

Exclusion Criteria:

* Known history of coronary or peripheral artery disease
* History of myocardial infarction
* Pregnant or lactating females
* Hypersensitivity to any ultrasound contrast agent
* Evidence right-to-left or bi-directional intracardiac shunt
* Moderate or greater valve disease other than from HCM (systolic anterior motion of the mitral valve)
* History of septal ablation or myectomy
* Hemodynamic instability
* Pacemaker dependent heart rhythm

Primary outcomes:
measure: Myocardial perfusion (ml/min/g) in the hypertrophied segment on myocardial contrast echo
timeFrame: One hour
measure: Myocardial blood flow reserve in the hypertrophied segment on myocardial contrast echo
timeFrame: One hour
Secondary outcomes:
measure: Spatial distribution of blood flow on myocardial contrast echocardiography
timeFrame: One hour
Other outcomes:
Locations:
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
Study officials:
References:
citation: Roldan P, Ravi S, Hodovan J, Belcik JT, Heitner SB, Masri A, Lindner JR. Myocardial contrast echocardiography assessment of perfusion abnormalities in hypertrophic cardiomyopathy. Cardiovasc Ultrasound. 2022 Sep 19;20(1):23. doi: 10.1186/s12947-022-00293-2.
Clinical trial NCT03574467: Functional Outcomes of The Bobath Approach on Patients With Brain Tumors: Comparison With Stroke Patients
Official title: Functional Outcomes of The Bobath Neurodevelopmental Treatment Approach Applied to Patients With Brain Tumors: Comparison With Stroke Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Brain Neoplasms
Stroke, Acute
Keywords: brain neoplasms
stroke
rehabilitation
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2018-07-02
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Department of Neurology between June 2016 and April 2017, were analyzed for the study. The study inclusion criteria were determined for all patients to be over 18 years of age, in the acute phase, Glasgow Coma Scale score 14 and above, Modifiye Rankin Score being more than 2 and medical stability. Furthermore, the criteria for inclusion in the study were unilateral stroke and having a stroke for the first time for stroke patients, and supratentorial location for patients with brain tumors.

Brief summary: The aim of this study is to examine the functional recovery results of the Bobath (NDT) approach in patients with primary brain tumors and compare the results with those of stroke patients.


Eligibility criteria: Inclusion Criteria:

* acute phase patients with brain tumor and stroke in after surgery

Exclusion Criteria:

* Modified rankin scale \<2
* High grade tumor
* Infratentorial tumor
* GCS\<14
* Rehabilitation session time\<3
* Second or more tumor surgery
* Second or more stroke
* Bilateral stroke

Primary outcomes:
measure: The Stroke Rehabilitation Assessment of Movement Measure (STREAM)
timeFrame: Patients were evaluated immediately before rehabilitation, and immediately after rehabilitation service, which lasted 4-10 days on average.
Secondary outcomes:
measure: The Functional Independent Measurement (FIM)
timeFrame: Patients were evaluated immediately before rehabilitation, and immediately after rehabilitation service, which lasted 4-10 days on average.
measure: Mini-Mental State Examination (MMSE)
timeFrame: Patients were evaluated immediately before rehabilitation, and immediately after rehabilitation service, which lasted 4-10 days on average.
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacettepe University
state: Altındağ
Study officials:
References:
Clinical trial NCT04475367: Evaluation of the Effect of an APP in Improving Treatment Adherence in Hypertensive Patients in Hypertension Ambulatory
Official title: Evaluation of the Effect of an APP in Improving Treatment Adherence in Hypertensive Patients in Hypertension Ambulatory
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Blood Pressure
Adhesion
Keywords: software
hypertension
technology
Lead sponsor: Instituto de Cardiologia do Rio Grande do Sul
Sponsor class: OTHER
First posted: 2020-07-17
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The participants will be randomized into 2 intervention groups
Primary purpose: SCREENING

Brief summary: Brief Summary: Through the App, the user will have the opportunity to connect directly with the health professional, clarify doubts and manage the treatment of their hypertension.

Detailed description: To evaluate treatment adherence and blood pressure reduction, through the HiperCross App, between two groups of hypertensive patients in a Hypertension Public Ambulatory in Porto Alegre.

The investigators hope to identify better adherence to treatment, as well as a significant reduction in blood pressure, all of these results will be better evaluated using the HiperCross application.

Eligibility criteria: Inclusion Criteria:

* hypertensive patients admitted to the hypertension clinic at Instituto de Cardiologia
* older 18 years

Exclusion Criteria:

* Patients without a mobile phone compatible with the App

Primary outcomes:
measure: Blood pressure value
timeFrame: 15 minutes
Secondary outcomes:
measure: Morisky scale
timeFrame: 15 minutes
Other outcomes:
Locations:
Study officials:
affiliation: Post Graduation professor - Cardiology Foundation
name: Bruna Eibel, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00743067: A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
Official title: A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Tumours
Keywords: XL880
MET inhibitor
GSK1363089
Solid Tumors
c-Met
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2008-08-28
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of oral daily GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subjects.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed solid tumor which is metastatic or unresectable with no known effective treatment measures,
* ECOG performance status of \</= 2.
* Adequate bone marrow reserve, hepatic, renal, and cardiovascular function,
* Negative pregnancy test.

Exclusion Criteria:

* Anticancer therapy within 30 days of the start of treatment,
* Received radiation to =25% of bone marrow within 30 days of treatment.
* Known brain metastasis,
* Uncontrolled intercurrent illness,
* HIV positive,
* Pregnant or breastfeeding women.

Primary outcomes:
measure: To determine the maximum tolerated dose (MTD) and to evaluate the safety and tolerability of daily oral administration of GSK1363089 in subjects with solid tumors
timeFrame: 2 years
Secondary outcomes:
measure: Plasma pharmacokinetics (PK) of daily GSK1363089 in subjects with solid tumors, pharmacodynamic effects of daily GSK1363089, Long-term safety and tolerability of daily GSK1363089, Tumor response after daily administration of GSK1363089
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, Keer H, Miles D, Muller T, Lorusso P. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest New Drugs. 2013 Jun;31(3):742-50. doi: 10.1007/s10637-012-9881-z. Epub 2012 Oct 6.
Clinical trial NCT02660840: Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations
Official title: Interventional, Open-label, Randomised, Crossover, Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations - Film Coated Tablet (Test Treatment) - 0.5 mg, 1 mg and 5 mg (H. Lundbeck A/S, Denmark) and Coated Tablet (Fluanxol®) - 0.5 mg, 1 mg and 5 mg (H. Lundbeck A/S, Denmark) in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Bioequivalence Study in Healthy Subjects
Lead sponsor: H. Lundbeck A/S
Sponsor class: INDUSTRY
First posted: 2016-01-21
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To establish bioequivalence between new film-coated tablet formulations of 0.5 mg, 1 mg and 5 mg flupentixol and the marketed coated tablet formulations of 0.5 mg, 1 mg, and 5 mg flupentixol, administered as single doses

Detailed description: All subjects will be confined to the clinic from Day -1 (Baseline) until Day 6 (120 hours post-dose) for each dosing period. First and second dosing will be separated by a washout period of at least 21 days

Eligibility criteria: Inclusion Criteria:

* body mass index (BMI) of ≥18.5 and ≤30 kg/m2
* The subject is, in the opinion of the investigator, generally healthy based on medical history, physical examination, vital signs, electrocardiogram (ECG), and the results of the haematology, clinical chemistry, urinalysis, serology, and other laboratory tests.

Exclusion Criteria:

* The subject is pregnant or breastfeeding.
* The subject has taken any investigational medicinal products 3 months prior to the first dose
* The subject has tested positive at the Screening Visit or at the Baseline Visit for drugs of abuse (opiates, methadone, cocaine, amphetamines \[including ecstasy\], barbiturates, benzodiazepines, and cannabinoids).

Other protocol defined inclusion and exclusion criteria may apply

Primary outcomes:
measure: The area under the plasma concentration-time curve
timeFrame: from 0 to 72 hours post-dose
measure: The maximum observed concentration (Cmax)
timeFrame: from 0 to 72 hours post-dose
Secondary outcomes:
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: RU801
Study officials:
affiliation: LundbeckClinicalTrials@Lundbeck.com
name: Email contact via H. Lundbeck A/S
role: STUDY_DIRECTOR
References: